²é¿´: 280  |  »Ø¸´: 1
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß ½›Ìì µÄ 7 ¸ö½ð±Ò

½›Ìì

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

[½»Á÷] ¡¾Ô­´´¡¿ÄÚº¬×Ó¹¦ÄÜÑо¿£¿

ÄÚº¬×ÓÔÚÉúÎïÌåÄÚ¾ßÓкܸߵıÈÀý£¬ÌرðÊǸߵÈÕæºËÉúÎ¹ØÓÚÄÚº¬×ӵŦÄܹúÄÚÍâ¶¼×öµ½Ê²Ã´Ë®Æ½ÁË£¬ÄÇλ¸ß¼¶³æ×ÓÖªµÀ£¬´Í½Ì°¡£¡
»Ø¸´´ËÂ¥
Ò»ÖÖÓëÊÀÎÞÕùµÄÉϽø£¬ÄÚÔڵļáÒãºÍÖÊÆÓÎÞ»ªµÄ´ó¶È£¡¡¾ÇîÎáÒ»Éú¶ø×·ÇóÖ®£¡¡¿
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yyn0452

ľ³æ (ÕýʽдÊÖ)


¡ï ¡ï ¡ï
1949stone(½ð±Ò+3): 2010-03-15 11:22
½›Ìì(½ð±Ò+3):лл »¹ÓÐÏà¹Ø×ÊÁÏÂ𣿠2010-03-15 13:26
ÓйØÄÚº¬×Ó¹¦ÄÜÑо¿µÄнøÕ¹

¡¡¡¡ÖлªÒ½Ñ§ÒÅ´«Ñ§ÔÓÖ¾2000ÄêµÚ17¾íµÚ3ÆÚ

ÍõÏþ±ó¡¡Áõ¹úÑö

¡¡¡¡ ¹Ø¼ü´Ê£ºÄÚº¬×Ó

¡¡¡¡ÈËÀà»ùÒò×龫ȷÍêÕûÐòÁеIJⶨ½«ÔÚ2003Äê֮ǰÍê³É¡£ÔÚ´ËÖ®ºó£¬ÈËÀà»ùÒò×鼯»®(human genome project, HGP)µÄÖØµã½«»á×ªÒÆµ½¶ÔÐòÁй¦ÄܵÄÑо¿¡£¾¡¹ÜÈËÃǶÔÐòÁй¦ÄÜÑо¿µÄÖ÷ÒªÁ¦Á¿ÈԻἯÖÐÔÚ±àÂëÐòÁУ¬µ«¶ÔÄÚº¬×Ó¼°»ùÒò¼äÐòÁй¦ÄܵÄÑо¿»áÔ½À´Ô½Êܵ½ÖØÊÓ£¬ÒòΪÕâЩÐòÁÐÕ¼ÈËÀà»ùÒò×éµÄ¾ø´ó²¿·Ö£¬µ«ÈËÃÇ¶ÔÆä¹¦ÄܵÄÁ˽âÈ´Ô¶ÉÙÓÚ¶Ô±àÂëÐòÁеÄÁ˽⡣ÎÒÃÇÄâ¶ÔĿǰÓйØÄÚº¬×ÓÑо¿×öÒ»¼òÒª×ÛÊö¡£

¡¡¡¡±àÂëÐòÁÐÖеÄÄÚº¬×Ó·ÖΪ3´óÀࣺµÚ1ÀàÊǵÚ1×åÄÚº¬×Ó(group ¢ñ introns)Ö÷Òª¼ûÓÚϸ°ûÆ÷(ÈçÏßÁ£Ìå)¡¢Ï¸¾ú¼°Ä³Ð©µÍµÈÕæºËϸ°û¡£µÚ2ÀàÊǵÚ2×åÄÚº¬×Ó(group ¢ò introns)Ò²Ö÷Òª¼ûÓÚϸ°ûÆ÷(ÈçÏßÁ£Ìå)¡¢Ï¸¾ú¡£µÚ1ÀàÄÚº¬×Ó·Ö²¼½ÏµÚ2ÀàÄÚº¬×ӹ㷺£¬µ«ÊÇÕâÁ½ÀàÄÚº¬×Ó²¢ÎÞÃ÷ÏÔµÄÁªÏµ£¬ËüÃÇÓи÷×Ô²»Í¬µÄ½á¹¹ÌØÕ÷£¬²¢ÇÒÄÜÐγÉÌØÕ÷ÐԵĶþ¼¶½á¹¹£¬µ«ËüÃÇÓÐÒ»¸ö¼«ÎªÖØÒªµÄ¹²Í¬µã£ºÄÜ×ÔÎÒ¼ôÇС£µÚ3ÀàÄÚº¬×Ó×îΪ³£¼û£¬¼´¾ø´ó¶àÊýÕæºËϸ°ûǰmRNAÖеÄÄÚº¬×Ó¡£

¡¡¡¡¶ÔǰÁ½ÀàÄÚº¬×ÓµÄÑо¿ÔøÒýÆðøѧ¸ÅÄîµÄÒ»´Î¸ïÃü¡£ÈËÃÇÔ­À´Ò»Ö±ÒÔΪֻÓе°°×ÖʲÅÓÐø»îÐÔ£¬µ«ºóÀ´·¢ÏÖµÚ1×åÄÚº¬×Ӻ͵Ú2×åÄÚº¬×ÓÔÚÌåÍâûÓÐÈκε°°×Öʸ¨ÖúµÄÌõ¼þϾÍÄÜÍê³É×ÔÉí¼ôÇУ¬½øÒ»²½µÄÑо¿±íÃ÷ËüÃÇ×ÔÉí¾Í¾ßÓÐø»îÐÔ¡£ÈËÃǰѾßÓÐø»îÐÔµÄRNAÃüÃûΪºËø(ribozyme)¡£Í¨¹ý¶ÔµÚ1ÀàÄÚº¬×ÓµÄÑо¿£¬ÈËÃÇ·¢ÏÖ²»µ«ËüÃÇ×ÔÉíÓÐø»îÐÔ£¬ËüÃǵÄһЩÑÜÉúÎïÈçL19RNAÒ²¾ßÓÐø»îÐÔ£¬¶øÇÒËüÃÇ»¹¾ßÓжàÖÖø»îÐÔ¡£ÕâÐ©ÌØµãʹËüÃdzÉΪ·Ö×ÓÉúÎïѧÑо¿µÄÖØÒª¹¤¾ß¡£Í¨¹ý¶ÔµÚ1ÀàÄÚº¬×Ó×ÔÎÒ¼ô½Ó»úÀíµÄÑо¿£¬ÈËÃÇ¿ÉÒÔÉè¼Æ³öʶ±ðÈÎÒ»ÌØÒìÐòÁеĺËø£¬ÄܶÔÈËÀà»ùÒò×éÐòÁй¦ÄܵÄÑо¿Ìṩ¼«´óµÄ°ïÖú¡£ÈËÃÇ»¹¿ÉÒÔÀûÓÃËüÄÜÌØÒìÐÔ¼ôÇÐRNAµÄÌØµã£¬Éè¼Æ³öÌØÒìÐÔ½µ½âijһ»ùÒòRNAµÄºËø£¬´Ó¶øÒÖÖÆÄ³Ð©»ùÒòµÄ±í´ï£¬×ª»ùÒò¶¯ÎïʵÑéµÄ½á¹ûÒÑ֤ʵÁËÕâÖÖ²ßÂÔµÄÓÐЧÐÔ£Û1£Ý¡£ÕâΪ»ùÒòÖÎÁÆÌṩÁËÒ»ÖÖȫеÄ˼·£ºÉè¼Æ³öÕë¶ÔijЩ²¡Ô­Î¢ÉúÎïRNAµÄºËøÒÔ¼°Õë¶ÔijЩ°©»ùÒòRNAµÄºËø¡£ÓÃÕâÖÖ·½·¨ÖÎÁÆHIV¸ÐȾÒѾ­½øÈëÒ»ÆÚÁÙ´²ÊÔÑé£Û2£Ý¡£ÓÃÕâÖÖ·½·¨ÖÎÁÆÂí·²ÊÏ×ÛºÏÕ÷ºÍ°×Ѫ²¡µÄÑо¿Ò²ÔÚ½øÐÐÖ®ÖУÛ3£¬4£Ý¡£

¡¡¡¡µÚ1ÀàÄÚº¬×ÓµÄÁ¬½Óø»îÐÔÄܰÑÒ»¶ÎÌØÒìµÄÐòÁÐÁ¬½Óµ½Ä³Ò»Ìض¨Î»µãµÄ3¡ä¶Ë£¬Õâ¿ÉÒÔ×÷Ϊ»ùÒòÖØ×éµÄÓÐЧ¹¤¾ß£¬ÀûÓÃÕâÒ»ÌØµã»¹¿ÉÒÔ½øÐжàÖÖ»ùÒòÍ»±äËùÖµÄÒÅ´«²¡µÄÖÎÁÆ£º½«Í»±ä²¿·ÖµÄRNA»»³ÉÕý³£µÄRNAÐòÁС£¾¡¹ÜÔÚºËøµÄÎȶ¨ÐÔ¡¢»îÐÔ¡¢¼°ÓÐЧµÄתÔË;¾¶µÈ·½Ã滹´æÔÚÐí¶àÎÊÌ⣬µ«ÓÐÒ»µãÊÇ¿ÉÒԿ϶¨µÄ£ººËøÔÚ½«À´µÄ»ùÒòÖÎÁÆÖбض¨»á´ó·Å¹â²Ê£Û5£Ý¡£ÒѾ­ÓÐÈËÔÚÑо¿ÓÃÕâÖÖ·½·¨ÖÎÁÆÁ­µ¶Ï¸°ûÐÔÆ¶Ñª£¬¼´ÔÚºËøµÄ½éµ¼Ï£¬ÓæÃ-Ѫºìµ°°×µÄ±àÂëÐòÁÐÈ¡´úmRNAÖÐÍ»±äµÄ¦Â-Ѫºìµ°°×±àÂëÐòÁУÛ6£Ý¡£µÚ1×åÄÚº¬×Ó»¹¿ÉÄÜÓëÒ»ÖÖеÄmRNAÐÞ¸´»úÀíÓйأÛ7£Ý¡£ÌåÍâRNAɸѡ¼¼ÊõÒѱ»ÓÃÓÚɸѡеĺͱäÒìµÄºËø£¬ÏÖÔÚºËøËùÄÜ×÷Óõĵ×ÎﷶΧÒÑ´ó´ó³¬¹ýÌìÈ»ºËøµÄ·¶Î§£Û8£Ý¡£LandweberµÈ£Û9£ÝÔÚɸѡºËøµÄʵÑéÖз¢ÏÖ£¬ËûÃÇ´ÓËæ»úRNAÐòÁÐÖÐɸѡµ½µÄÁ½ÖÖºËøֻÐëÓÐ7¸ö¼î»ùÊDZ£Êص쬼´Ê×ÏÈÔÚËÄĤ³æµÚ1×åÄÚº¬×ÓÖз¢ÏÖµÄþÀë×ÓÒÀÀµµÄ×ÔÎÒ¼ôÇлùÐò£¬»¹·¢ÏÖÕâÁ½ÖÖøͬʱ¾ßÓÐÁ¬½Óø»îÐÔ£¬ÕâЩ½á¹û˵Ã÷¼òµ¥µÄRNAø·Ç³£ÈÝÒ×Ðγɣ¬¶øÔÚÕâЩø´ß»¯µÄ»ù´¡ÉÏ£¬ÄܺܿìÐγɽϸ´ÔÓµÄRNA·Ö×Ó£¬ÎªÅªÇåÉúÃüÆðÔ´ÎÊÌâÌṩÁËÖØÒª×ÊÁÏ¡£1998Ä꣬ÈËÃÇ»¹ÔÚÔ­ÉúÉúÎïÖз¢ÏÖÁËÒ»ÀàеĵÚ1×åÄÚº¬×Ó¡£ÂÏÉúÄÚº¬×Ó£¬ËüÊÇÒ»ÖÖ¿ÉÒÆ¶¯µÄÄÚº¬×Ó£¬³¤Ô¼1.3¡«1.4 kb£¬RNAˮƽµÄ½á¹¹·Ç³£¸´ÔÓ£¬°üº¬Á½ÖÖ¹¦Äܲ»Í¬µÄºËø£¬»¹ÓÐÒ»¶Î±àÂëºËËáÄÚÇÐøµÄÐòÁС£ÕâÒ»Çж¼ºÁÎÞÒÉÎʵÄ˵Ã÷Ëü½«³ÉΪһÖַdz£ÓÐÓõķÖ×ÓÉúÎïѧ¹¤¾ß£Û10£Ý¡£

¡¡¡¡¶ÔµÚ2×åÄÚº¬×Ó´ß»¯»úÖÆµÄÑо¿Ò²ÓÐÁ˽ϴóµÄ·¢Õ¹£¬¶ÔÆäD5½á¹¹ÓòÖб£ÊصÄÄñàÑßʵÄ×÷ÓÃÓÐÁ˽øÒ»²½µÄÈÏʶ¡£·¢ÏÖÔ­À´Ò»Ö±ÈÏΪÄÑÒÔ½Ó½üµÄRNAÂÝÐý´ó¹µÔÚ´ß»¯Öз¢»ÓÁËÖØÒª×÷Óã¬ÌرðÊDZ£ÊØÄñàÑßʵÄÁ½¸öÔÓÔ­×Ó¶ÔÍê³É·´Ó¦ÖÁ¹ØÖØÒª£Û11£Ý¡£µÚ2ÀàÄÚº¬×ӵļôÇйý³ÌÓëµÚ3ÀàÄÚº¬×Ó¼«ÎªÏàËÆ£¬¾ùÐγÉÌ×Ë÷×´½á¹¹¡£ÈËÃǾݴËÍÆ²âsnRNA¿ÉÄÜÓɵÚ2ÀàÄÚº¬×Ó½ø»¯¶øÀ´¡£µÚ1ºÍµÚ2ÀàÄÚº¬×ÓÖг£º¬ÓÐÄÜ·­Òë³Éµ°°×µÄ¿ª·ÅÔĶÁ¿ò£¬Ö÷Òª±àÂëºËËáÄÚÇÐø£¬Äæ×ªÂ¼Ã¸µÈ£¬ÕâʹËüÃdzÉΪ¿ÉÒÆÔËÔª¼þ(mobile element)¡£Õâµã¶ÔÁ˽âÄÚº¬×ӵįðÔ´¼°½ø»¯ÓÐÒ»¶¨°ïÖú¡£

¡¡¡¡µÚ3ÀàÄÚº¬×Ó¾¡¹Ü×îΪ³£¼û£¬µ«ÎÒÃÇ¶ÔÆä¹¦ÄܵÄÁ˽âÈ´×îÉÙ¡£ÓÐÒ»¸ö¹¦ÄÜÊDz»Ö¤×ÔÃ÷µÄ£ºÓÉÓÚÄÚº¬×ӵĴæÔÚʹ¸ßµÈÉúÎï¶ÔÍ»±äµÄÄÍÊÜÄÜÁ¦´ó´óÔöÇ¿ÁË¡£ÒòΪÔڸߵÈÉúÎïÖУ¬ÄÚº¬×ӵij¤¶ÈÔ¶´óÓÚÍâÏÔ×Ó£¬´ó²¿·ÖËæ»úÍ»±ä»á·¢ÉúÔÚÄÚº¬×ÓÖУ¬¶ÔÉúÎï²»»áÓÐÑÏÖØÓ°Ï졣Ŀǰ·¢ÏÖµÚ3ÀàÄÚº¬×ÓΨһµÄ¹²Í¬µãÊǾù×ñÊØGU-AG·¨Ôò¡£Ôڴ󲿷ֻùÒòµÄ½ø»¯¹ý³ÌÖУ¬ÎÒÃÇ¿ÉÒÔ¿´³öÄÚº¬×ÓÔÚ»ùÒòÖеÄλÖÃÊÇÏ൱±£Êص쬵«ÆäƬ¶ÎµÄ³¤¶È¼°ÐòÁÐÔòÎÞÃ÷ÏԵı£ÊØÐÔ¡£ÓйØÎ»Öñ£ÊصÄÔ­Òò¼°ÒâÒ壬ÎÒÃÇÉв»µÃ¶øÖª¡£

¡¡¡¡ÕâÀàÄÚº¬×ӵľ«È·¼ô½ÓÐèÒªÒì³£¸´Ôӵļô½ÓÌåÀ´Íê³É£¬Í¬Ê±»¹Êܵ½Ðí¶àÒòËØµÄÓ°Ïì¡£KanµÈ£Û12£ÝÔÚIgM»ùÒòÖз¢ÏÖËüµÄijЩÄÚº¬×ӵļôÇÐÊܵ½Á½¸ö×÷ÓÃÏ໥Þ׿¹µÄ¼ôÇÐÔöÇ¿×ÓºÍÒÖÖÆ×ӵĵ÷½Ú£¬¶øÇÒÕâÁ½¸öµ÷½ÚÔª¼þ¾ÍλÓÚÕâ¸ö»ùÒòµÄÍâÏÔ×ÓÄÚ¡£Ðí¶à»ùÒòµÄ±äλ¼ôÇл¹Óë×éÖ¯ÌØÒìÐÔÓйء£MauduitµÈ£Û13£Ý±¨µÀ¸Éϸ°ûÒò×Ó(SCF)»ùÒòµÄÁ½ÖÖ±í´ï²úÎïÊÇÓÉÆäǰmRNA±äλ¼ôÇÐËùÖ£¬ÕâÖÖ±äλ¼ôÇпÉÄÜÊÇÓÉϸ°ûÄÚµÄpHÖµ¾ö¶¨µÄ¡£HayakawaµÈ£Û14£ÝÒ²±¨µÀ³ÖÐøËáÐԴ̼¤ÄÜÓÕµ¼Ò»ÖÖµ÷½ÚÒò×Ó²úÉúµÄÏÖÏó£¬ÕâÖÖÒò×Ó¶ÔÈËÀàATPºÏ³Éø¦ÃÑǵ¥Î»µÄǰmRNAµÄ±äλ¼ôÇÐÆð¸ºµ÷½Ú×÷Ó᣶ÔÕâÀàÄÚº¬×Ó¼ô½Ó»úÀíµÄÑо¿²»µ«ÓÐÀûÓÚÎÒÃǶÔÔçÆÚÒÅ´«ÏµÍ³·Ö×Ó½ø»¯µÄÁ˽⣬¶øÇÒÓÐÀûÓÚ¶ÔÏÖÔÚÕæºË»ùÒòµÄ±í´ïÀí½â¡£µ«ÊǼô½ÓÌåµÄ½á¹¹¹ýÓÚ¸´ÔÓ£¬Ä¿Ç°µÄ¼¼ÊõÉÐÎÞ·¨³¹µ×ŪÇåÆä½á¹¹¡£ÏÖÔÚÖ÷ÒªÊÇÓÃϵͳµÄ¸Ä±äÆä·´Ó¦»ùÍŵķ½·¨À´ÍÆ¶ÏÆä·´Ó¦»úÀí£Û15£Ý¡£

¡¡¡¡Ä¿Ç°´ó¶àÊýÓëÄÚº¬×ÓÓйصÄÒýÆð¼²²¡µÄÍ»±ä¼¯ÖÐÔÚÄÚº¬×ÓÓëÍâÏÔ×ӵĽ»½ç(¼´GU»òAG)£¬´Ó¶øµ¼ÖÂÍâÏÔ×ÓµÄȱʧ£¬»òÄÚº¬×Óδ±»¼ôÇжøÒýÆðÍ»±ä¡£ÄÚº¬×ÓÖмäµÄ±äÒìÒ²¶àÊÇÒòΪ¼¤»îÁËÒþÐÔ¼ôÇÐλµãÓ°ÏìÁ˼ôÇвŵ¼Ö¼²²¡¡£Õâ·½ÃæµÄÀý×ÓÒѺܶࡣ¶ÔÆä¼ôÇлúÀíµÄ³ä·ÖÁ˽âÎÞÒÉ»á´Ù½øÎÒÃǶÔÕâЩ¼²²¡µÄÁ˽⣬ΪÖÎÁÆ´òÏ»ù´¡¡£

¡¡¡¡È»¶ø£¬×î½üµÄÑо¿·¢ÏÖÓÐЩÄÚº¬×ÓÖмäµÄ¼î»ù±äÒ쾡¹Ü²»Ó°Ïì¼ôÇÐÒ²¿ÉÄÜÓë¼²²¡Óйء£ÈçBrockmollerµÈ£Û16£Ý·¢ÏÖϸ°ûÉ«ËØP450 1A2»ùÒòµÚ1¸öÄÚº¬×ÓÖеÄC/A¶à̬ÐÔÓëÒ»ÖÖ¸ßÓÕµ¼ÐÔÃÜÇÐÏà¹Ø£¬µ±ÓÐÎüÑÌϰ¹ß»òN-ÒÒõ£»ù×ªÒÆÃ¸»îÐԽϵÍ(slow NAT2)µÄ¸öÌå¾ßÓÐÕâÖÖ¸ßÓÕµ¼ÐÔʱ£¬¸Ã»ùÒò»áÔÚ°òë×°©Öйý¶È±í´ï¡£Ô½À´Ô½¶àµÄÑо¿·¢ÏÖÄÚº¬×Ó¿ÉÄÜÓë»ùÒò±í´ïµÄµ÷¿ØÓйء£TosiµÈ£Û17£Ý¶ÔÈË¡¢ÊóC1»ùÒò½øÐÐͬԴÐòÁбȽϣ¬²¢¶ÔC1»ùÒòµÄÆô¶¯×ÓÇøºÍµÚ1¸öÄÚº¬×ÓÖеı£ÊØÐòÁеŦÄܽøÐÐÑо¿£¬·¢ÏÖËüÃǾù¾ßÓе÷¿Ø×÷ÓᣵÚ3ÀàÄÚº¬×Ó²»¾ßÓбàÂ빦ÄܵĸÅÄîÒѱ»´òÆÆ¡£MalletµÈ£Û18£Ý·¢ÏÖ±àÂëÄÒ×´ÒÒõ£µ¨¼îתÔËÌåµÄ»ùÒò¾ÍλÓÚµ¨¼îÒÒõ£»ù×ªÒÆÃ¸»ùÒòµÄµÚ1¸öÄÚº¬×ÓÖС£ÕâÁ½¸ö»ùÒò¸÷×ÔµÄÆô¶¯×Ó¶¼ÒÑÕÒµ½£¬µ«ËüÃDZí´ïµÄµ÷¿ØÉÐÔÚ½øÒ»²½Ñо¿Ö®ÖС£GregoireµÈ£Û19£Ý·¢ÏÖGATA-3»ùÒòµÄµÚ1¸öÄÚº¬×ÓÊÇÒ»¸ö·Ç³£Ç¿µÄת¼¼¤»îÒò×Ó£¬ÓÐλÖÃÒÀÀµÐÔµ«Ã»ÓÐϸ°ûÀàÐÍÌØÒìÐÔ¡£KimµÈ£Û20£ÝÔòͨ¹ý½«²»Í¬³¤¶ÈµÄHNET»ùÒò5¡äƬ¶ÎÁ¬½Óµ½±¨¸æ»ùÒò£¬¹¹½¨³öÓлòûÓеÚ1¸öÄÚº¬×ӵıí´ïϵͳ£¬ËûÃǵÄÑо¿½á¹ûÏÔʾ£ºµÚ1¸öÄÚº¬×ӶԸûùÒòϸ°ûÌØÒìµÄ³ä·Ö±í´ïÊDZز»¿ÉÉٵġ£KlettµÈ£Û21£Ýͨ¹ýÀàËÆµÄ·½·¨¶ÔÊóM1¶¾Þ¦¼îÊÜÌå»ùÒò½øÐÐÑо¿Ò²·¢ÏÖ°üº¬´ÓÆô¶¯×ÓÑÓÉìÖÁµÚ2ÄÚº¬×ӵᬶÎÔÚÔöÇ¿»ùÒò±í´ï·½ÃæÒªÔ¶Ç¿ÓÚÖ»°üÀ¨Æô¶¯×Ó¡¢µÚ1ÍâÏÔ×Ó£¬¼°²¿·ÖµÚ1ÄÚº¬×ӵį¬¶Î¡£

¡¡¡¡×ÛÉÏËùÊö£¬ÈËÃǶÔÄÚº¬×Ó¹¦ÄܵÄÑо¿Éд¦ÓÚÆð²½½×¶Î£¬¶ÔÄÚº¬×Ó¹¦ÄܵÄÑо¿¼ÈÊÇÈËÀà»ùÒò×éÐòÁй¦ÄÜÑо¿µÄÒ»²¿·Ö£¬ÓÖÄÜΪÎÒÃÇÑо¿±àÂëÐòÁй¦ÄÜÌá¹©ÖØÒª¹¤¾ß£¬´Ù½ø¶Ô»ùÒò±í´ïµ÷¿ØµÄ½øÒ»²½Àí½â¡£Í¬Ê±£¬ÄÚº¬×Ó»¹¿ÉÄÜÌṩÓйØÉúÃüÆðÔ´½ø»¯µÄ´óÁ¿ÐÅÏ¢¡£Ëæ×ÅÕâ·½Ãæ¹¤×÷µÄÉîÈ룬ÈËÃÇÍêÈ«¶Á¶®ÈËÀà»ùÒò×éÐòÁÐÕâ±¾ÉúÃü°ÂÃØÖ®Êé¡¢¶ø²»½ö½öÊDZàÂëÐòÁÐÕâһС²¿·ÝµÄÈÕ×Ó½«ºÜ¿ì»áµ½À´¡£

×÷Õßµ¥Î»£ºÍõÏþ±ó£¨100005±±¾©£¬Öйúҽѧ¿ÆÑ§Ôº»ù´¡Ò½Ñ§Ñо¿Ëù¡¡ÖйúЭºÍÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÒÅ´«ÊÒ£©

¡¡¡¡Áõ¹úÑö£¨100005±±¾©£¬Öйúҽѧ¿ÆÑ§Ôº»ù´¡Ò½Ñ§Ñо¿Ëù¡¡ÖйúЭºÍÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÒÅ´«ÊÒ£©

²Î¿¼ÎÄÏ×

£Û1£ÝAmlage B, Luzi E, Eckstein F. Designing ribozymes for the inhibition of gene expression. Trends Biotechnol, 1998,16¡Ã434-438.

¡¡¡¡£Û2£ÝWelch PJ, Barber JR, Wong-Staal F. Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr Opin Biotechnol,1998,9¡Ã486-496.

¡¡¡¡£Û3£ÝKilpatrick MW, Phylactou LA. Towards an RNA-based therapy for Marfan syndrome. Mol Med Today, 1998,4¡Ã376-381.

¡¡¡¡£Û4£ÝMatsushita H, Kobayashi H, Kizaki M, et al.Therapeutic application for leukemia with ribozyme. Rinsho Ketsueki, 1998,39¡Ã553-564.

¡¡¡¡£Û5£ÝPhylactou LA, Kilpatrick MW, Wood MJ. Ribozymes as therapeutic tools for genetic disease. Hum Mol Genet, 1998,7¡Ã1649-1653.

¡¡¡¡£Û6£ÝWeatherall DJ. Gene therapy:repairing haemoglobin disorders with ribozymes. Curr Biol,1998,8¡Ã696-698.

¡¡¡¡£Û7£ÝCech T. Group I introns:new molecular mechanisms for mRNA repair. Biotechnology, 1995,13¡Ã323-326.

¡¡¡¡£Û8£ÝPan T. Novel and variant ribozymes obtained through in vitro selection. Curr Opin Chem Biol,1997,1(1)¡Ã17-25.

¡¡¡¡£Û9£ÝLandweber LF, Pokrovskaya ID. Emergence of a dual-catalytic RNA with metal-specific cleavage and ligase activities:the spandrels of RNA evolution. Proc Natl Acad Sci U S A, 1999,96¡Ã173-178.

¡¡¡¡£Û10£ÝEinvik C, Elde M, Johansen S. Group ¢ñ twintrons:genetic elements in myxomycete and schizopyrenid amoeboflagellate ribosomal DNAs. Biotechnology,1998,64¡Ã63-74.

¡¡¡¡£Û11£ÝKonforti BB, Abramovitz DL, Duarte CM, et al.Ribozyme catalysis from the major groove of group ¢ò intron domain 5. Mol Cell,1998,1¡Ã433-441.

¡¡¡¡£Û12£ÝKan JL, Green MR. Pre-mRNA splicing of IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer and inhibitor. Genes Dev, 1999,13¡Ã462-471.

¡¡¡¡£Û13£ÝMauduit C, Chatelain G, Magre S, et al.Regulation by pH of the alternative splicing of the stem cell factor pre-mRNA in the testis. J Biol Chem,1999,274¡Ã770-775.

¡¡¡¡£Û14£ÝHayakawa M, Endo H, Hamamoto T, et al.Acidic stimulation induces a negative regulatory factor that affects alternative exon selection in vitro in human ATP synthase gamma-subunit pre-mRNA.Biochem Biophys Res Commun, 1998,251¡Ã603-608.

¡¡¡¡£Û15£ÝSontheimer EJ. Bridging sulfur substitutions in the analysis of pre-mRNA splicing. Methods,1999,18(1)¡Ã29-37.

¡¡¡¡£Û16£ÝBrockmoller J, Cascorbi I, Kerb R, et al.Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol Lett,1998,102-103¡Ã173-183.

¡¡¡¡£Û17£ÝTosi M. Molecular genetics of C1 inhibitor. Immunobiology, 1998,199¡Ã358-365.

¡¡¡¡£Û18£ÝMallet J, Houhou L, Pajak F, et al.The cholinergic locus:ChAT and VAChT genes. Physiol Paris, 1998,92¡Ã145-147.

¡¡¡¡£Û19£ÝGregoire JM, Romeo PH. T-cell expression of the human GATA-3 gene is regulated by a non-lineage-specific silencer. J Biol Chem,1999,274¡Ã6567-6578.

¡¡¡¡£Û20£ÝKim CH, Kim HS, Cubells JF, et al.A previously undescribed intron and extensive 5¡ä upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem,1999,274¡Ã6507-6518.

¡¡¡¡£Û21£ÝKlett CP, Bonner TI. Identification and characterization of the rat M1 muscarinic receptor promoter. J Neurochem, 1999,72¡Ã900-909.
2Â¥2010-03-15 10:44:34
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ½›Ìì µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çóµ÷¼Á +4 Zhangbod 2026-03-21 5/250 2026-03-22 11:27 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] ¿¼Ñе÷¼Á +3 À´ºÃÔËÀ´À´À´ 2026-03-21 3/150 2026-03-22 11:24 by ÑîÑîÑî×Ï
[¿¼ÑÐ] 0856²ÄÁÏר˶353Çóµ÷¼Á +4 NIFFFfff 2026-03-20 4/200 2026-03-22 09:49 by 2026paper
[¿¼ÑÐ] ÉúÎïѧ071000 329·ÖÇóµ÷¼Á +4 ÎÒ°®ÉúÎïÉúÎﰮΠ2026-03-17 4/200 2026-03-22 08:34 by hxsm
[¿¼ÑÐ] 328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑо­Àú +5 ÉúÎ﹤³Ìµ÷¼Á 2026-03-17 9/450 2026-03-21 23:32 by zhujy1982
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á +5 @taotao 2026-03-21 5/250 2026-03-21 20:55 by lbsjt
[¿¼ÑÐ] 326Çóµ÷¼Á +5 ŵ±´¶û»¯Ñ§½±êéê 2026-03-15 8/400 2026-03-21 19:33 by ColorlessPI
[¿¼ÑÐ] Çóµ÷¼Á +3 13341 2026-03-20 3/150 2026-03-21 18:28 by ѧԱ8dgXkO
[¿¼ÑÐ] 330Çóµ÷¼Á0854 +3 assdll 2026-03-21 3/150 2026-03-21 13:01 by ²«»÷518
[¿¼ÑÐ] 332Çóµ÷¼Á +3 ·ï»ËÔº¶¡Õæ 2026-03-20 3/150 2026-03-21 10:27 by luoyongfeng
[¿¼ÑÐ] Çóµ÷¼Á +6 Mqqqqqq 2026-03-19 6/300 2026-03-21 08:04 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á +5 ÊØºòϦÑôCF 2026-03-18 5/250 2026-03-21 01:06 by JourneyLucky
[¿¼ÑÐ] ²ÄÁÏרҵÇóµ÷¼Á +6 hanamiko 2026-03-18 6/300 2026-03-21 00:24 by JourneyLucky
[¿¼ÑÐ] 311Çóµ÷¼Á +5 ¶¬Ê®Èý 2026-03-18 5/250 2026-03-21 00:16 by JourneyLucky
[¿¼ÑÐ] 294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶ +15 ݤÎÉ­ÁÖ 2026-03-18 15/750 2026-03-20 23:28 by JourneyLucky
[¿¼ÑÐ] 298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á +9 ÊÖ»úÓû§ 2026-03-17 9/450 2026-03-20 14:24 by ÎÞи¿É»÷111
[¿¼ÑÐ] ²ÄÁÏѧ˶318Çóµ÷¼Á +5 February_Feb 2026-03-19 5/250 2026-03-19 23:51 by 23Postgrad
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +5 pupcoco 2026-03-17 8/400 2026-03-19 13:58 by houyaoxu
[¿¼ÑÐ] 277µ÷¼Á +5 ×ÔÓɼå±ý¹û×Ó 2026-03-16 6/300 2026-03-17 19:26 by Àîleezz
[˶²©¼ÒÔ°] ºþ±±¹¤Òµ´óѧ ÉúÃü¿ÆÑ§Ó뽡¿µÑ§Ôº-¿ÎÌâ×éÕÐÊÕ2026¼¶Ê³Æ·/ÉúÎï·½Ïò˶ʿ +3 1ϲ´º8 2026-03-17 5/250 2026-03-17 17:18 by ber´¨cool×Ó
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û